Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Beijer Byggmaterial in connection with its acquisition of AB Knut Lindgren
Mandate

Vinge advises Beijer Byggmaterial in connection with its acquisition of AB Knut Lindgren

November 22, 2021 Employment and Benefits M&A Corporate Commercial Environmental Law

Vinge has advised Beijer Byggmaterial AB in connection with its acquisition of AB Knut Lindgren. AB Knut Lindgren, known as Lindgrens Bygg & Järn, is a family owned company with two facilities situated in Tingsryd and Urshult in Småland.

Vinges team consisted of, amongst others, Jonas Bergström, Joacim Rydergård and Vilhelm Rondahl (M&A), Frida Ställborn (Real Estate/Lease Agreements), Lina Österberg (Environment), Mika Jordan (Corporate Commercial), Nicklas Thorgerzon (GDPR), Ebba Svenburg and Elin Broman (Employment Law).

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024